News

Higher Medicine Announces Strategic Investment by Cerdwen to Accelerate Therapies for Kabuki Syndrome and Other Brain Disorders

Higher Medicine Inc.  announced a strategic investment and fundraising partnership with Cerdwen, a venture capital firm focused on health and performance technology innovation.

Based in West Chester, Pennsylvania, Cerdwen partners with visionary founders to advance transformative healthcare technologies, supporting the translation of bold scientific ideas into meaningful clinical and commercial impact.

“Higher Medicine exemplifies the type of company we seek to partner with: rigorous science, a focused initial indication, and a platform capable of expanding into significant unmet medical needs,” said Kevin Brophy, Managing Principal of Cerdwen. “Dr. Kim and his team are tackling complex CNS disorders with a differentiated epigenetic approach, and we believe the company is well-positioned to translate that ambition into clinical impact.”

“Higher Medicine was founded on a simple but ambitious belief: that many devastating brain disorders need not be lifelong sentences,” said Dr. Leo Kim, Founder and CEO of Higher Medicine. “By harnessing epigenetic biology, we aim to prevent, slow, or even reverse conditions that few companies are willing to confront. Our initial focus on Kabuki syndrome is a deliberate entry point into a broader platform that can be extended to multiple high-unmet-need CNS indications such as CTE and Alzheimer’s disease. With Cerdwen’s investment, we will heighten the momentum for the seed round and accelerate toward clinical proof-of-concept.”

“This investment represents a strong validation of Higher Medicine’s scientific vision and execution,” said Marie Mazur, Board Member of the Mid-Atlantic Diamond Venture (MADV). “It also highlights the power of MADV’s regional biotech network and quarterly Forums, as this partnership originated from our December pitch event.”

The investment was completed via a Simple Agreement for Future Equity (SAFE) and closed on December 31, 2025. The transaction advances Higher Medicine’s Seed Expansion financing and marks a key milestone toward first-in-human clinical studies.

Read more here.

Recent News

01/27/2026

Higher Medicine Announces Strategic Investment by Cerdwen to Accelerate Therapies for Kabuki Syndrome and Other Brain Disorders

Higher Medicine Inc.  announced a strategic investment and fundraising partnership with Cerdwen, a venture capital firm focused on health and performance technology innovation. Based in West Chester, Pennsylvania, Cerdwen partners with visionary founders to advance transformative healthcare technologies, supporting the translation of bold scientific ideas into meaningful clinical and commercial impact. “Higher Medicine exemplifies the

01/27/2026

Epidarex Capital Announces First Close of Fund IV, Securing $145 Million to Build the Next Wave of Life Science Startups

Epidarex Capital (“Epidarex”), a transatlantic life science venture firm, today announces the first close of Epidarex Capital IV, LP, securing more than $145 million in commitments to build therapeutics and medical device companies. The Fund’s initial investors include the British Business Bank, Strathclyde Pension Fund, the Scottish National Investment Bank, as well as leading family

01/20/2026

Vibrent Health Joins a Landmark BARDA-Funded Large-Scale Hybrid/Remote Decentralized Clinical Research Study

Vibrent Health, a leading software-as-a-service (SaaS) data company in the field of precision medicine research, is collaborating with Fred Hutch Cancer Center (Fred Hutch) under a $17 million contract awarded through the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV) Consortium. This collaboration drives critical research on correlates of protection (CoPs),